isotretinoin has been researched along with Keratosis* in 35 studies
9 review(s) available for isotretinoin and Keratosis
Article | Year |
---|---|
WITHDRAWN: Interventions for photodamaged skin.
Topics: Administration, Cutaneous; Dermatologic Agents; Humans; Isotretinoin; Keratosis; Laser Therapy; Nicotinic Acids; Randomized Controlled Trials as Topic; Skin Aging; Skin Diseases; Sunlight; Tretinoin | 2015 |
Interventions for photodamaged skin.
Photodamage describes skin changes such as fine and coarse wrinkles, roughness, freckles and pigmentation changes that occur as a result of prolonged exposure to the sun. Many treatments are available to reverse the damage, but it is unclear which work and at what cost in terms of unwanted side effects.. To assess the effects of topically applied treatments, tablet treatments, laser and surgical procedures for photodamaged skin.. We searched the Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library, Issue 1 2002, MEDLINE (1966-June 2002), EMBASE (1974-June 2002), Health Periodicals (1976-June 2002). We checked references of articles and communicated with authors and the pharmaceutical industry.. Randomised controlled trials which compared drug or surgical interventions with no treatment, placebo or another drug, in adults with mild, moderate or severe photodamage of the face or forearms.. Two reviewers independently extracted data and assessed trial quality.. Thirty studies of variable quality were included. Eight trials showed that topical tretinoin cream, in concentrations of 0.02% or higher, was superior to placebo for participants with mild to severe photodamage on the face and forearms (although losses to follow-up were relatively high in most studies). For example, the relative risk of improvement for 0.05% tretinoin cream, compared to placebo (three studies), at 24 weeks, was 1.73 (95% confidence interval 1.39 to 2.14). This effect was not seen for 0.001% topical tretinoin (one study) or 0.01% (three studies). A dose-response relationship was evident for both effectiveness and skin irritation. One small within-patient study showed benefit from topical ascorbic acid compared with placebo. Tazarotene (0.01% to 0.1%) and isotretinoin (0.1%) both showed significant improvement over placebo for moderate photodamage (one study each). There is limited evidence (one trial), to show that the effectiveness of 0.05% tretinoin, is equivalent to the effects of 0.05% and 0.1% tazarotene. One small study showed greater improvement in upper lip wrinkles with CO2 laser technique compared to Baker's phenol chemical peel, at 6 months. Three small RCTs comparing CO2 laser with dermabrasion found no difference in wrinkle score at 4 to 6 months, suggesting that both methods are equally efficacious, but more erythema was reported with the laser. The effectiveness of other interventions such as hydroxy acids and natural polysaccharides was not clear.. There is conclusive evidence that topical tretinoin improves the appearance of mild to moderate photodamage on the face and forearms, in the short term. However erythema, scaling/dryness, burning/stinging and irritation may be experienced initially. There is limited evidence that tazarotene and isotretinoin benefit patients with moderate photodamage on the face: both are associated with skin irritation and erythema. The effectiveness of other interventions remains uncertain. Topics: Administration, Cutaneous; Dermatologic Agents; Humans; Isotretinoin; Keratosis; Laser Therapy; Nicotinic Acids; Randomized Controlled Trials as Topic; Skin Aging; Skin Diseases; Sunlight; Tretinoin | 2005 |
Keratosis lichenoides chronica.
Keratosis lichenoides chronica is a rare dermatosis characterized by a distinctive seborrheic dermatitis-like facial eruption, together with violaceous, papular, and nodular lesions on the extremities and trunk typically arranged in a linear and reticulate pattern. We describe a patient with KLC who had the typical features of this disease and responded partially to treatment with oral isotretinoin. Topics: Adult; Biopsy, Needle; Chronic Disease; Diagnosis, Differential; Female; Humans; Isotretinoin; Keratolytic Agents; Keratosis; Lichenoid Eruptions; Remission Induction; Skin | 1998 |
A case of atrophoderma vermiculatum responding to isotretinoin.
Atrophoderma vermiculatum (AV) is a rare disorder leading to reticular or honeycomb scarring of the face and responding poorly to treatment. A case is now presented of the successful induction of remission in the inflammatory component of the disease following a prolonged course of isotretinoin; improvement was then maintained after cessation of the treatment. In severe cases of AV with significant scarring, a trial of isotretinoin therapy is thus worthwhile in an attempt to stop progression of the disease and improve its cosmetic appearance. Topics: Child; Facial Dermatoses; Female; Humans; Isotretinoin; Keratolytic Agents; Keratosis | 1998 |
Results of the use of vitamin A and retinoids in cutaneous malignancies.
Topics: Animals; Etretinate; Humans; Isotretinoin; Keratosis; Mycosis Fungoides; Retinoids; Skin Neoplasms; Vitamin A | 1989 |
Bone changes associated with oral retinoid therapy.
Topics: Administration, Oral; Animals; Bone Diseases; Etretinate; Humans; Hyperostosis, Diffuse Idiopathic Skeletal; Isotretinoin; Keratosis; Retinoids | 1989 |
Acne vulgaris in childhood. Pathogenesis and management.
Acne vulgaris is a common skin disorder. Although it is most prevalent in the second decade of life, its beginnings are heralded by increased activity of the sebaceous glands and faulty follicular keratinization, which are already evident in mid to late childhood. The subsequent and increasing proliferation of the follicular anaerobic diphtheroid microflora contribute further as an important pathogenic factor in the generation of inflammatory lesions. Treatments of acne, therefore, are aimed at reducing the follicular anaerobic bacteria, counteracting the follicular hyperkeratosis, and inhibiting the activity of sebaceous glands. Topics: Acne Vulgaris; Adolescent; Anti-Bacterial Agents; Anti-Infective Agents, Local; Bacterial Infections; Benzoyl Peroxide; Child; Child, Preschool; Female; Humans; Infant; Infant, Newborn; Isomerism; Isotretinoin; Keratosis; Male; Propionibacterium acnes; Sebaceous Glands; Sebum; Tretinoin; Triamcinolone Acetonide | 1986 |
Synthetic retinoids in dermatology.
The potential of vitamin A, or retinol, in the treatment of a variety of skin diseases has long been recognized, but because of serious toxic effects this substance generally could not be used. The recent development and marketing of two relatively non-toxic synthetic analogues, which are known as retinoids, has made it possible to treat some of the diseases that are resistant to standard forms of therapy. Isotretinoin is very effective in cystic and conglobate acne, while etretinate is especially useful in the more severe forms of psoriasis. Good results have also been obtained in other disorders of keratinization. Vitamin A and its derivatives apparently have an antineoplastic effect as well and may come to be used in both the prevention and the treatment of epithelial cancer. In many of these diseases the retinoids act by enhancing the normal differentiation and proliferation of epidermal tissues, but the exact mechanisms are not well understood. Their influence on the intracellular polyamines that control the synthesis of nucleic acids and proteins may be an important factor. Although the retinoids have few serious systemic effects, they are teratogenic, and because they persist in the body their use in women of childbearing potential is limited. Topics: Acne Vulgaris; Bone Diseases; Chemical and Drug Induced Liver Injury; Etretinate; Female; Humans; Isomerism; Isotretinoin; Keratosis; Kinetics; Psoriasis; Skin Diseases; Skin Neoplasms; Tretinoin; Triglycerides; Vitamin A | 1985 |
Oral synthetic retinoid treatment in children.
The synthetic retinoids are a new class of drugs which are highly effective in the treatment of a broad spectrum of dermatologic disease. In this report 15 patients with chronic disorders of keratinization and one patient with severe cystic acne were treated with oral isotretinoin. The degree of clinical response and duration of post-treatment remission varied with the different disorders. Acute side effects were predominantly limited to the skin and mucous membranes and were reversible after discontinuation of treatment in these patients. Acute retinoid toxicity and the potential for developing chronic toxicity are reviewed. In an attempt to facilitate the monitoring of dermatologic patients treated with oral synthetic retinoids, we present our current guidelines for the use of these agents. Topics: Acne Vulgaris; Adolescent; Animals; Bone Diseases; Child; Child, Preschool; Etretinate; Humans; Isomerism; Isotretinoin; Joint Diseases; Keratosis; Mice; Psoriasis; Skin Diseases; Tretinoin | 1983 |
3 trial(s) available for isotretinoin and Keratosis
Article | Year |
---|---|
Clinical evaluation of topical isotretinoin in the treatment of actinic keratoses.
Retinoids have been shown to improve the manifestations of skin photodamage, including actinic keratoses.. The efficacy and tolerability of isotretinoin 0.1% cream in the treatment of actinic keratoses were evaluated in a randomized, double-blind, placebo-controlled, parallel-group study.. One hundred patients were randomly assigned to treatment with 0.1% cream or vehicle twice daily for 24 weeks to the face, the scalp, and the upper extremities. Patients were assessed every 4 weeks by the investigators, who counted and recorded the number of lesions in each treatment area. The 93 patients who had at least one postbaseline assessment were included for efficacy analysis. Local tolerability was evaluated at each study visit.. On the face, the reduction in number of actinic keratoses (mean +/- SEM) at the end of treatment was greater for patients treated with isotretinoin (3.9 +/- 0.6, i.e., 66% of patients with a reduction > 30%) than with placebo (1.7 +/- 0.5, i.e., 45% of patients with a reduction > 30%); this difference was statistically significant (p = 0.001). No significant drug effect was seen for lesions on the scalp or upper extremities. Mild to moderate local reactions with isotretinoin abated with reduced treatment frequency.. Our results suggest that isotretinoin 0.1% cream cannot compete with more rapid treatments of actinic keratoses. However, its effect on facial lesions may be beneficial during long-term treatment of associated sun-damaged skin. Topics: Administration, Topical; Arm; Double-Blind Method; Facial Dermatoses; Humans; Isotretinoin; Keratosis; Scalp Dermatoses; Sunlight | 1994 |
Topical tretinoin in actinic keratosis and basal cell carcinoma.
In several studies between 1962 and 1978, topical tretinoin was proved capable of producing complete regression of actinic keratosis and basal cell carcinoma. But because its efficacy is not comparable to that of other modalities, topical tretinoin is currently used only as an adjunct to topical 5-fluorouracil in the treatment of actinic keratosis. One recent report found topical tretinoin ineffective in the chemoprevention of actinic keratosis. Although the oral synthetic retinoids isotretinoin and etretinate have been used in the prevention and treatment of cutaneous malignancy, the potential exists for chronic toxicity from the prolonged systemic therapy that appears necessary for maintaining the chemopreventive effect. For this reason, it may be appropriate to study further the preventive as well as therapeutic effects of topical tretinoin and other retinoids for actinic keratosis and skin cancer. If they prove safe and effective, the use of topical retinoids in the prevention and treatment of cutaneous tumors may be the most significant clinical application of these drugs. Topics: Carcinoma, Basal Cell; Clinical Trials as Topic; Etretinate; Humans; Isotretinoin; Keratosis; Photosensitivity Disorders; Skin Neoplasms; Tretinoin; Urinary Bladder Neoplasms | 1986 |
Isotretinoin: a review.
Topics: Clinical Trials as Topic; Humans; Ichthyosis; Isotretinoin; Keratosis; Pityriasis Rubra Pilaris; Skin Diseases; Tretinoin | 1983 |
23 other study(ies) available for isotretinoin and Keratosis
Article | Year |
---|---|
Acantholytic Dyskeratosis Post-COVID-19 Vaccination: Another Case With Rapid Response to Isotretinoin.
Topics: Acantholysis; COVID-19; COVID-19 Vaccines; Humans; Isotretinoin; Keratosis | 2023 |
Effective treatment of papular acantholytic dyskeratosis with oral isotretinoin.
Topics: Acantholysis; Administration, Oral; Adult; Female; Humans; Isotretinoin; Keratosis; Recurrence | 2007 |
Multiple minute digitate hyperkeratosis.
Topics: Adult; Biopsy, Needle; Female; Follow-Up Studies; Humans; Immunohistochemistry; Isotretinoin; Keratosis; Male; Middle Aged; Severity of Illness Index; Treatment Outcome; Upper Extremity | 2002 |
Bilateral nipple hyperkeratosis treated successfully with topical isotretinoin.
A 22-year-old woman presented with bilateral thickening and hyperpigmentation of her nipples since the age of 17 years. There was no history of pregnancy or oral contraceptive pill use. Isotretinoin 0.025% gel was applied twice daily and the lesions disappeared in 4 weeks. After the drug was ceased, recurrence appeared within 4 months. The same therapy, applied for 2 weeks, again cleared the problem. Topics: Administration, Cutaneous; Adult; Female; Humans; Isotretinoin; Keratosis; Nipples | 1999 |
Waxy keratoses of childhood.
Three cases of waxy keratoses of childhood occurring in two families are described. The disorder seen in these three cases appears to be clinically and histopathologically distinct from previously described familial disorders of keratinization, which also feature multiple discrete papules. Topics: Child; Child, Preschool; Diagnosis, Differential; Family; Female; Humans; Isotretinoin; Keratosis | 1994 |
A case of ulerythema ophryogenes responding to isotretinoin.
Topics: Adult; Eyebrows; Facial Dermatoses; Female; Humans; Isotretinoin; Keratosis | 1993 |
Kyrle's disease. Effectively treated with isotretinoin.
Kyrle's disease is an uncommon dermatologic entity with characteristic clinical and histopathologic features. A case is recorded in a 63-year-old man undergoing hemodialysis for chronic renal failure. Systemic isotretinoin treatment for 13 weeks resulted in a complete clearance of the cutaneous lesions. Systemic treatment is effective and could be considered preferred therapy. Topics: Eccrine Glands; Hair; Humans; Isotretinoin; Keratosis; Kidney Failure, Chronic; Male; Middle Aged; Renal Dialysis | 1993 |
[New lipid biochemical aspects in the pathogenesis of a follicular keratinization disorder in acne vulgaris].
Follicular hyperkeratinization of the epithelium of the acroinfundibulum of sebaceous follicles is one of the primary events in the pathogenesis of acne vulgaris. Oral treatment with 13-cis-retinoic acid can reduce these hyperkeratoses. In order to determine whether follicular hyperkeratinization is related to disturbances of epidermal follicular lipids, we analyzed the lipids of initial comedones from 10 patients with nodulocystic acne before and after a 6th weeks oral therapy with 13-cis-retinoic acid (0.7 mg/kg body weight). The treatment with retinoid resulted in a significant increase of epidermal lipids (free sterols: +34%; ceramides: +19%, whereas the lipids of sebaceous origin decreased (glycerides: -36%). The mass ratio of free sterols to cholesterol sulfate increased by 86% compared to pre-treatment levels. These findings support the hypothesis that local follicular deficiencies of epidermal lipids due to increased sebum secretion might induce abnormal follicular keratinization. Topics: Acne Vulgaris; Adult; Chromatography, Thin Layer; Female; Humans; Isotretinoin; Keratosis; Lipid Metabolism; Male; Sebum | 1988 |
Skeletal changes associated with chronic isotretinoin and etretinate administration.
The skeletal changes associated with systemic retinoid therapy reflect the influence of retinoids on differentiating systems. Although skin is usually the intended target, treatment with retinoids often results in abnormalities of ossification and calcification. The effects of retinoids on bone may be profound and include progressive calcification of ligaments and tendon insertions, premature fusion of epiphyses, modeling abnormalities of long bones, and perhaps osteoporosis. Although it has been known since 1933 that vitamin A cause bone abnormalities, the mechanism of this effect has been elusive. Recent work suggests a possible relationship of the retinoids with several cytokines, which results in enhanced maturation of the preosteoclast. The increasing number of significant bone changes, including posterior lumbar vertebral osteophytosis, make skeletal toxicity the principle risk factor of chronic systemic retinoid therapy. Topics: Drug Administration Schedule; Etretinate; Humans; Isotretinoin; Keratosis; Ossification, Heterotopic; Radiography; Spinal Osteophytosis; Tretinoin | 1987 |
Retinoids in disorders of keratinization: their use in children.
During the last 10 years we treated 39 children with severe keratinization disorders with the aromatic retinoid etretinate. Six of these children were followed-up for 8-9 years. Mucocutaneous serum enzymatic and lipid side effects of etretinate were mild, transient and well tolerated. Osseous side effects were present after 4-6 years in all our 6 patients on prolonged retinoid therapy. Asymptomatic osseous neoformation and osseous reabsorption in the absence of calcium, phosphate, and alkaline phosphatase serum alterations have been observed. The growth and development curves and the sexual development of our patients (with exception of a patient with Rud's syndrome) have been normal. Osteoporosis and slender diaphysis were often present at initiation of therapy. On the basis of our findings and recent reports of the literature we suggest restricting retinoid therapy of keratinizing disorders in children to conditions severe enough to be physically, psychologically or socially incapacitating. In an attempt to reduce the risk of chronic toxicity and possibly to allow regression of initial bone alterations, intermittent therapy and combination therapy are recommended. Topics: Adolescent; Bone Diseases; Child; Drug Administration Schedule; Drug Therapy, Combination; Etretinate; Female; Humans; Isotretinoin; Keratosis; Male; Tretinoin | 1987 |
Erythrokeratodermia variabilis treated with isotretinoin. A clinical, histologic, and ultrastructural study.
A 30-year-old woman with erythrokeratodermia variabilis was treated with oral isotretinoin for four months. Clinical and light and electron microscopic observations were made before and after treatment. A characteristic electron microscopic feature was subnormal numbers of keratinosomes within the stratum granulosum of hyperkeratotic plaques. Isotretinoin therapy resulted in almost complete clinical clearing of these plaques and restoration of normal numbers of epidermal keratinosomes. In addition, distinctive dyskeratotic cells containing clumped tonofilaments were observed within the stratum granulosum by electron microscopy. These cells persisted after retinoid treatment. Topics: Adult; Biopsy; Epidermal Cells; Erythema; Female; Humans; Isotretinoin; Keratins; Keratoderma, Palmoplantar; Keratosis; Microscopy, Electron; Skin; Time Factors; Tretinoin | 1986 |
Keratotic lupus erythematosus: treatment with isotretinoin.
We describe a patient with a distinct verrucous variant of chronic discoid lupus erythematosus manifested by skin lesions resembling keratoacanthomas. The diagnosis of keratotic lupus was confirmed by characteristic immunofluorescence and ultrastructural findings and by an initial response to antimalarial therapy. Combination therapy with isotretinoin and hydroxychloroquine resulted in control of her previously refractory skin lesions, and the isotretinoin apparently played a key role in this improvement. Topics: Aged; Biopsy; Drug Therapy, Combination; Female; Humans; Hydroxychloroquine; Isomerism; Isotretinoin; Keratosis; Lupus Erythematosus, Discoid; Skin; Tretinoin | 1986 |
Isotretinoin and Staphylococcus aureus infection. A possible association.
The use of isotretinoin (13-cis-retinoic acid) in the treatment of numerous dermatologic disorders, as well as the side effects encountered with use of the drug, have increased remarkably since its release. We encountered a case of Staphylococcus aureus endocarditis in a patient with chronic stable aortic insufficiency undergoing therapy with isotretinoin for extensive actinic keratoses. Although significant dysfunction of the immune system has not been demonstrated with isotretinoin, nasal colonization with S aureus has been shown to occur. Changes in skin fragility caused by the drug may provide a portal of entry for the organism. Physicians should be alert for this potential complication in patients with an underlying cardiac valvular lesion; antibiotic prophylaxis may be indicated in this group during isotretinoin therapy. Topics: Aortic Valve Insufficiency; Endocarditis, Bacterial; Humans; Isomerism; Isotretinoin; Keratosis; Male; Middle Aged; Risk; Skin; Staphylococcal Infections; Staphylococcus aureus; Tretinoin | 1986 |
Erythrokeratodermia variabilis.
Topics: Humans; Isotretinoin; Keratosis; Tretinoin | 1986 |
Acquired pili torti in two patients treated with synthetic retinoids.
A mother and daughter with epidermolytic hyperkeratosis were treated with two different synthetic retinoids at different times. Both patients exhibited the previously unreported side effect of increased curliness of scalp hair. Light microscopic examination revealed pili torti during the administration of isotretinoin. Both patients also experienced a better therapeutic response to and more hair loss with etretinate than with isotretinoin. Topics: Adolescent; Adult; Female; Hair; Hair Diseases; Humans; Isotretinoin; Keratosis; Tretinoin | 1985 |
Isotretinoin therapy is associated with early skeletal radiographic changes.
Eight patients with disorders of keratinization (six with ichthyosis, one with Darier's disease, and one with palmar-plantar keratoderma) were treated with isotretinoin for 9 months (1 patient) to 1 year (7 patients). The patients ranged from 5 to 26 years of age. The average isotretinoin dose was 2 mg/kg/day (range, 1.0-2.9 mg/kg/day). Radiographic skeletal surveys were performed prior to therapy, and after 6 months and 1 year of therapy. After 1 year of isotretinoin treatment, six of the eight patients had small but unequivocal skeletal hyperostoses. Five of the patients had multiple hyperostoses. While only two patients were judged to have hyperostoses after 6 months of isotretinoin therapy during prospective evaluation, retrospective comparison with the radiographs obtained after 1 year revealed skeletal hyperostoses after 6 months of treatment in an additional three patients. Between 6 months and 1 year of therapy, some of the hyperostoses remained unchanged while others had progressed. In three patients, hyperostoses were seen at 12 months that were not detectable at 6 months. Based on this prospective study of skeletal changes during isotretinoin therapy, we recommend that patients taking high doses of isotretinoin for long periods be monitored radiographically. Topics: Adolescent; Adult; Bone and Bones; Child; Child, Preschool; Exostoses; Female; Humans; Isotretinoin; Keratosis; Male; Prospective Studies; Radiography; Retrospective Studies; Time Factors; Tretinoin | 1984 |
Pachyonychia congenita. Electron microscopic and epidermal glycoprotein assessment before and during isotretinoin treatment.
Two patients, a father and son, with pachyonychia congenita were treated with orally administered isotretinoin because the extreme deformity and discomfort associated with their massive keratoderma interfered with their work and school, respectively. While clinical benefits could not be sustained, electron microscopic findings compatible with suppression of abnormal keratinization were observed. In addition, skin biopsy samples were analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and the gels were then subjected to a lectin overlay technique with concanavalin A labeled with iodine 125. The distribution of specific glycoproteins was found to be different for lesional as against normal epidermis. The procedure was repeated after oral treatment with isotretinoin. The labeled glycoprotein pattern of the lesional epidermis was clearly distinguishable from both the pretreatment lesional and the normal epidermis; it was mostly intermediate between the two. The normal epidermis was virtually unaffected by the retinoid treatment. Topics: Adult; Child; Glycoproteins; Humans; Isotretinoin; Keratosis; Male; Microscopy, Electron; Nail Diseases; Skin; Tretinoin | 1984 |
Early skeletal hyperostoses secondary to 13-cis-retinoic acid.
Prolonged therapy with retinoid drugs (chemically similar to vitamin A) often results in skeletal hyperostoses, similar to those seen in idiopathic skeletal hyperostosis. Eight patients, aged 5-26 years, with dermatologic disorders were treated with 13-cis-retinoic acid. Skeletal surveys were obtained before and during treatment. In 1 year, six of the eight patients had developed such skeletal hyperostoses in both axial and appendicular regions. The cervical spine was the most common site of involvement. None of the children demonstrated accelerated skeletal maturation. Two of the patients had mild musculoskeletal discomfort during this period. The findings indicate that high-dose 13-cis-retinoic acid therapy may cause skeletal hyperostoses, requiring radiographic monitoring during prolonged periods of treatment. An implication of these observations, relating to the etiology of idiopathic skeletal hyperostosis, is discussed. Topics: Adolescent; Adult; Bone Diseases, Developmental; Child; Child, Preschool; Female; Humans; Isotretinoin; Keratosis; Male; Prospective Studies; Radiography; Spine; Time Factors; Tretinoin | 1984 |
[Indications for retinoids].
Topics: Etretinate; Humans; Isotretinoin; Keratosis; Psoriasis; Skin; Skin Diseases; Tretinoin | 1983 |
Premature epiphyseal closure in a child receiving oral 13-cis-retinoic acid.
A boy with epidermolytic hyperkeratosis was treated systemically for 4 1/2 years with 13-cis-retinoic acid. At the age of 10 1/2 years, he developed pain in his right knee and radiographic evidence of partial closure of the proximal epiphysis of the right tibia. Similar radiographic changes have been described in individuals ingesting excessive amounts of vitamin A. Topics: Bone Diseases; Child; Epiphyses; Humans; Isotretinoin; Keratosis; Male; Tibia; Tretinoin | 1982 |
Oral retinoids. Broad-spectrum dermatologic therapy for the 1980s.
Topics: Acne Vulgaris; Animals; Cocarcinogenesis; Etretinate; Humans; Immunity; Isomerism; Isotretinoin; Keratosis; Polyamines; Psoriasis; Skin; Skin Diseases; Teratogens; Tretinoin; Triglycerides; Vitamin A | 1981 |
Elevation of serum triglyceride levels from oral isotretinoin in disorders of keratinization.
Ten patients with disorders of keratinization were treated with oral isotretinoin (13-cis-retinoic acid) on an investigational protocol to test the efficacy, safety, and optimal dosage schedule for using the drug in these rare disorders. Elevations of serum triglyceride levels above the highest normal levels developed in seven of the ten patients, while they maintained normal levels of serum cholesterol. This effect was found to be dose and/or time related and reversible. Moderate elevations of serum triglyceride levels have not been clearly established as a risk factor for the development of coronary artery disease. High levels, however, may precipitate acute pancreatitis. For this reason, the conditions of patients receiving retinoids must be carefully monitored for triglyceride abnormalities throughout their courses of treatment. Topics: Administration, Oral; Adolescent; Adult; Child; Cholesterol; Darier Disease; Female; Humans; Isotretinoin; Keratins; Keratosis; Male; Middle Aged; Skin; Skin Diseases; Tretinoin; Triglycerides | 1980 |
Inhibition of hamster buccal pouch carcinogenesis by 13-cis-retinoic acid.
Sixty-four male and female Syrian hamsters, 3 months of age and weighing 90 to 120 grams, were divided into four equal experimental groups. In animals of Groups 1 and 2 the left buccal pouch was painted three times weekly with a 0.5% solution of DMBA in heavy mineral oil. Group 2 animals also received 10 mg. of 13-cis-retinoic acid in peanut oil administered orally twice a week by pipette. Carcinogen retinoid were administered on alternate days. Group 3 animals served as controls, receiving only 13-cis-retinoic acid. Group 4 animals served as untreated controls. Four animals in each group (two males and two females) were killed at 10, 12, 14, and 16 weeks. The Group 2 animals, which received 13-cis-retinoic acid, exhibited a significant delay in DMBA carcinogenesis of buccal pouch mucosa, as studied both grossly and histologically. Both groups eventually demonstrated well-differentiated epidermoid carcinomas, but the tumors were smaller in the DMBA-retinoid animals. Topics: Animals; Carcinoma, Papillary; Carcinoma, Squamous Cell; Cheek; Cricetinae; Female; Isotretinoin; Keratosis; Leukoplakia, Oral; Male; Mesocricetus; Mouth Mucosa; Mouth Neoplasms; Neoplasms, Experimental; Tretinoin | 1980 |